At ASGCT 2026 in Boston, Genethon presented new clinical data from three of its gene therapy programs in Duchenne muscular dystrophy, gamma-sarcoglycanopathy (LGMD-R5), and Crigler-Najjar syndrome. In total, Genethon teams presented 8 oral presentations and 13 posters.
Genethon, the French laboratory dedicated to the research and development of gene therapies for rare diseases created by AFM-Telethon, presented several clinical results at the annual meeting of the American Society of Gene & Cell Therapy (ASGCT), held from May 11 to 15, 2026, in Boston, USA.
Genethon teams presented a total of 8 oral presentations and 13 posters covering several gene therapy programs currently in clinical development.
